Studieoverzicht
Study name: TIL in NSCLC
| Histology | NSCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | LUMC |
| Enrollment | Recruiting |
| Therapy line | Later line (≥2L) |
| Design |
Fase 1 monocenter single-arm interventie studie |
| Intervention | TIL therapie icm carboplatin-paclitaxel (cohort B ook pembrolizumab) |
| Key outcome parameters | Safety en tolerability |
| Key inclusion criteria | Stadium IV NSCLC met progressie na PD-L1 inhibitor of chemo-immunotherapie (of stabiele ziekte na 2 kuren PD-L1 inhibitor) Resectabele laesie voor TIL product |
| Key exclusion criteria | Symptomatische CNS metastase of van >1cm Steroiden (equivalent >10mg prednison) |
| Contact information | Log in voor de contactinformatie |